2024
Chapter 30 The emerging genetic landscape of renal cell carcinoma
Lee G, Shinder B, Sadimin E, Stephenson R, Singer E. Chapter 30 The emerging genetic landscape of renal cell carcinoma. 2024, 447-460. DOI: 10.1016/b978-0-12-822824-1.00035-3.ChaptersRenal cell carcinomaCell carcinomaOrgan-confined renal cell carcinomaKidney cancerMetastatic renal cell carcinomaLong-term survival outcomesLandscape of renal cell carcinomaDiagnosis of kidney cancerRenal tubule epithelial cellsTubule epithelial cellsGroup of diseasesSurgical resectionSystemic therapyDistant metastasisSurvival outcomesDiagnosed patientsEpithelial cellsPatientsPatient deathGenetic landscapeCarcinomaDiseaseCancerResectionMetastasis
2023
Predictive Biomarkers in Advanced Renal Cell Carcinoma
Shinder B, Kronstedt S, Hakimi A. Predictive Biomarkers in Advanced Renal Cell Carcinoma. 2023, 251-268. DOI: 10.1007/978-3-031-40901-1_11.ChaptersRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaPredictive biomarkersEra of treatment optionsCharacteristics of renal cell carcinomaPrediction of treatment responseOptimal therapeutic pathwayTargeted systemic therapyImmuno-oncology agentsRoutine clinical useSystemic therapyAdvanced diseaseClinical benefitTreatment responseTreatment optionsClinical useTherapeutic pathwaysCarcinomaPatientsBiomarkersMolecular characteristicsTherapy
2020
Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery.
Patel H, Shinder B, Srinivasan R, Singer E. Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. Current Opinion In Oncology 2020, 32: 240-249. PMID: 32195679, PMCID: PMC9788417, DOI: 10.1097/cco.0000000000000621.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellChemotherapy, AdjuvantClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCytoreduction Surgical ProceduresHumansKidney NeoplasmsNeoadjuvant TherapyNeoplasm MetastasisProtein Kinase InhibitorsRandomized Controlled Trials as TopicConceptsMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaBiology of metastatic renal cell carcinomaTreatment of metastatic renal cell carcinomaManagement of metastatic renal cell carcinomaTyrosine kinase inhibitor cabozantinibProgrammed cell death protein 1 antibodyIntroduction of novel therapiesCombination of axitinibFirst-line therapyUS Food and Drug AdministrationFood and Drug AdministrationCytoreductive surgeryAdvanced RCCSystemic therapyCombination therapySurvival benefitTargeted therapyPatient selectionTreatment paradigmNovel therapiesTherapeutic advancesCombinatorial therapyTreatment advances
2017
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach
Shinder B, Rhee K, Farrell D, Farber N, Stein M, Jang T, Singer E. Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Frontiers In Oncology 2017, 7: 107. PMID: 28620578, PMCID: PMC5449498, DOI: 10.3389/fonc.2017.00107.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMetastatic renal cell carcinomaRenal cell carcinomaSystemic therapyCell carcinomaSurgical managementSurgical management of patientsImmune checkpoint inhibitorsNeoadjuvant systemic therapyMetastatic kidney cancerCytokine-based immunotherapyOptimal patient selectionManagement of patientsCheckpoint inhibitorsCytoreductive surgeryMetastatic diseasePrimary tumorAdjuvant therapyProspective trialsTherapeutic armamentariumPatient selectionKidney cancerTherapyCarcinomaSurgeryPatients